

## Drug and Therapeutics Committee – Minutes – approved

<b>Date / Time</b>	11 <sup>th</sup> June 2015
<b>Venue</b>	The Committee Room, Alderson House, HRI
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs Wendy Hornsby, Senior Pharmacy Technician.
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Dr M Miller, Senior Principal Pharmacist, Interface Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mrs C Grantham, Medicines Management Nurse Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU Dr O Ogunbambi, Consultant Rheumatologist Dr H Klonin, Consultant Paediatrician
-------------------	---

<b>Apologies</b>	Mr P Renwick, Vascular Surgeon, HEY Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Prof M Lind, Vice Chair, Professor of Oncology
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.06.01	<b>Apologies</b>	As above.					
2015.06.02	<b>Declarations of Interest</b>	There were no declarations of interest.	Noted.	No further action			6/15
2015.06.03	<b>Minutes of the previous meeting</b>	The minutes were accepted as a true record.	Noted	No further action			6/15
2015.06.04	<b>Action Tracker</b>	<p>NICE Guidance MM has written to diabetes team and requested the place of Empagliflozin in treatment pathway</p> <p>D&amp;T Attendance Has been raised at surgery governance and Darren Walkley has agreed to attend.</p> <p>Any Other Business ML/SG to request acute pain team discuss use of opiate conversion chart. ML to discuss with Dr Sampu.</p> <p>Apologies DC has spoken to patient experience team and begun process of recruiting a new lay member. New Action:AM to write to Mrs Beal and thank her for her contribution to D&amp;T</p> <p>New Product Requests AM has written to applicants and WH has updated formulary</p>	<p>Action complete</p> <p>Action complete</p> <p>ML/SG not present to discuss</p> <p>Action complete</p> <p>Action complete</p>	<p>No further action</p> <p>No further action</p> <p>Discuss next time</p> <p>AM to write to Mrs Beal.</p> <p>No further action</p>	<p>MM</p> <p>SG</p> <p>ML/SG</p> <p>DC AM</p> <p>AM/WH</p>	<p></p> <p></p> <p>5/15</p> <p>7/15</p> <p></p>	<p>6/15</p> <p>6/15</p> <p></p> <p>6/15</p> <p>6/15</p>

		<p>New Product Requests POB has spoken to Dr S Walton who has requested the dermatology speciality nurse develop pathway to include secukinumab</p>	Action complete	No further action	POB		6/15
		<p>MHRA DSU MM has written to dermatology and renal teams re: Hydoxyzine</p>	Action complete	No further action	MM		6/15
		<p>IFR Flow chart Flow chart has been escalated to OQC. POB has discussed with Dr Patmore, who requested IFR be more frequently referred to medical director if included use of trial for compassionate use or the use of unlicensed products.</p>	Action complete	No further action	WH		6/15
		<p>Antibiotic Formulary AM has written to ACAT and informed them of the committees decision</p>	Action complete	No further action	AM		6/15
		<p>Unlicensed list WH has added new unlicensed list to intranet</p>	Action complete	No further action	WH		6/15
		<p>Correspondence Received WH has updated formulary to include Urgotul SSD use by TVN nurse</p>	Action complete	No further action	WH		6/15
		<p>Correspondence Received Dr Maravayas to be asked to submit a new product request. This was for Pembrolizumab due to a report published by the Early Access to Medicines Scheme (EAMS). The committee agreed that all future EAMS should be discussed at D&amp;T to give trust approval.</p>	ML not present to discuss	Discuss next time	ML		6/15
			All future EAMS reports to be discussed at D&T	POB to discuss further at next D&T meeting.	POB	7/15	
				DC to circulate presentation from	DC	7/15	

		AOB Daclatasvir has been added to formulary	Action complete	SMPC meeting No further action	WH		6/15
2015.06.06	<b>New Product Requests</b>	<p>Golimumab – Dr Tsai Application submitted in line with TA329.</p> <p>Apremilast – Plaque Psoriasis - Dr Walton Apremilast – Psoriatic Arthritis - Dr Ogunbambi POB informed the committee that he had received a letter in support of the application from Dr Bagguely. SMC has accepted for use for both indications Psoriatic Arthritis and Plaque Psoriasis. The preparation is provided free until NICE is published. If NICE refuse will continue to provide for free if NICE approve will be commissioned by CCG's</p> <p>During the discussion DC informed the committee he had several FOI requests which could have been answered if there was public access to the intranet.</p>	<p>Approved</p> <p>Approved for both conditions.</p>	<p>MM to write to Dr Tsai/Sebastian to ask if gastro have treatment pathway in place.</p> <p>MM to write to Dr Walton/Dr Ogunbambi/Dr Bagguely as committee agreed they would like to see treatment pathway for both conditions</p> <p>AM to write to applicants and WH to update formulary</p> <p>WH to arrange for D&amp;T minutes to be placed on HERPC website</p>	<p>MM</p> <p>MM</p> <p>AM/WH</p> <p>WH</p>	<p>7/15</p> <p>7/15</p> <p>7/15</p>	
2015.06.06	<b>NICE Guidance</b>	<p>NG9 Bronchiolitis in Children MM has reviewed guidance and all drugs are on trust formulary, MM also informed the committee that current HEY guidance is not in line with NICE. HEY guidance to be updated to include “consultant recommendation only, not recommended for simple bronchiolitis”, for drug treatments not recommended by NICE.</p>	<p>HK to request update to current trust guidance</p>		<p>HK</p>	<p>7/15</p>	

		NG11 Challenging behaviour and learning disabilities:prevention and interventions for people with learning disabilities whose behaviour challenges. All drugs on formulary, no issues.	Noted	No further action			
2015.06.07	<b>MHRA Drug Safety update</b>	Contents noted	Noted	No further action			6/15
2015.06.08	<b>Minutes from Safe Medication Practice Committee</b>	Paper to be written on management of medical gases and forwarded to executive committee.	Noted	No further action			6/15
2015.06.09	<b>Minutes from the Hull &amp; East Riding Prescribing Committee</b>	MM highlighted that a new guideline had been written in conjunction with pathology for treatment with B12 and folic acid. The guideline recommends the use of oral cyanocobalamin to determine if deficiency is dietary. Cyanocobalamin is currently non formulary.	The committee agreed to add oral cyanocobalamin to formulary	Update formulary	WH	7/15	
2015.06.11	<b>Correspondence Received</b>	Diabetes team have requested line extension for Humalog 200units/ml Kwikpen .Concerns around potential errors discussed – only available as pen, with once click per unit. POB informed the committee that the MHRA recognises this and has plans to make all insulins available as prefilled pens in the future and to remove vials and cartridges completely.	Line extension approved	Update formulary	WH	7/15	
2015.06.10	<b>Chairs Approvals</b>	Selinexor – CLL & AML – Dr S Ali Apremilast – Dystrophic Nails – Dr S Walton	Noted	No further action			6/15
2015.06.13	<b>Issues to escalate to</b>	No issues to escalate	No further action				6/15

	<b>Operational Quality Committee</b>						
2015.06.14	<b>Any other Business</b>	NHSE Treatment of Chronic Hepatitis C in Patients with Cirrhosis Commissioning policy recommends use of some agents not yet available on formulary. Dr Moss has requested that these agents are made available asap. Patients must be approved by specialist centre before agents can be prescribed. Some of these agents are unlicensed however there are no current licensed products available for these genotypes.	D&T agreed that HEY can supply subject to commissioning arrangements for treatment agreed with specialist centres.	POB to discuss further with Dr Moss.	POB	7/15	
2015.06.15	<b>Date and Time of Next Meeting</b>	Thursday 9 <sup>th</sup> July 2015, 8.15am – 9.30am. The Board Room, Alderson House, HRI					